Page last updated: 2024-12-06

metaclazepam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ka-2547: benzodiazepine deriv [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71272
CHEMBL ID1290783
CHEBI ID135621
SCHEMBL ID433172
MeSH IDM0110854

Synonyms (35)

Synonym
talis
metuclazepam
brometazepam
metaclazepam
ka-2547
kc-2547
1h-1,4-benzodiazepine, 7-bromo-5-(2-chlorophenyl)-2,3-dihydro-2-(methoxymethyl)-1-methyl-
metaclazepam [inn]
metaclazepamum [inn-latin]
7-bromo-5-(o-chlorophenyl)-2,3-dihydro-2-(methoxymethyl)-1-methyl-1h-1,4-benzodiazepine
CHEBI:135621
7-bromo-5-(2-chlorophenyl)-2-(methoxymethyl)-1-methyl-2,3-dihydro-1,4-benzodiazepine
metaclazepamum
84031-17-4
c2n2b1303l ,
unii-c2n2b1303l
CHEMBL1290783
metaclazepam [who-dd]
metaclazepam [mi]
7-bromo-5-(2-chlorophenyl)-2,3-dihydro-2-(methoxymethyl)-1-methyl-1h-1,4-benzodiazepine
SCHEMBL433172
65517-27-3
WABYCCJHARSRBH-UHFFFAOYSA-N
J-690360
EX-A890
FT-0700372
BCP19109
ka 2547; ka-2547; ka2547
DTXSID40905121
Q6822419
kc 2547; ka 2547; metaclazepam; metuclazepam; talis; talis (pharmaceutical)
metaclazepam free base
84031-17-4 (free base)
7-bromo-5-(2-chlorophenyl)-2-(methoxymethyl)-1-methyl-2,3-dihydro-1h-benzo[e][1,4]diazepine
AKOS040753008

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Two dosage regimens were compared by a randomized two-way crossover design: a once-a-day dosing (15 mg metaclazepam in the evening, = A) versus a twice-a-day dosing (5 mg in the morning plus 10 mg in the evening, = B) over ten days in twelve healthy male volunteers."( Pharmacokinetic profile of metaclazepam (Talis), a new 1.4-benzodiazepine. Influence of different dosage regimens on the pharmacokinetic profile of metaclazepam and its main metabolite under steady-state conditions.
Achtert, G; Gielsdorf, W; Hausleiter, HJ; Molz, KH; Philipp, P,
)
0.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodiazepineA group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (87.50)18.7374
1990's1 (6.25)18.2507
2000's0 (0.00)29.6817
2010's1 (6.25)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.54 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (38.89%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (61.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]